Illumina - ILMN Stock Forecast, Price & News

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 2 sell ratings, 6 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ILMN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.
View ILMN analyst ratings or view top-rated stocks.

16 brokers have issued twelve-month price objectives for Illumina's shares. Their ILMN share price forecasts range from $150.00 to $350.00. On average, they expect the company's stock price to reach $249.40 in the next twelve months. This suggests a possible upside of 14.5% from the stock's current price.
View analysts price targets for ILMN or view top-rated stocks among Wall Street analysts.

Illumina's stock was trading at $202.20 at the start of the year. Since then, ILMN stock has increased by 7.7% and is now trading at $217.82.
View the best growth stocks for 2023 here.

Illumina saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 4,910,000 shares, an increase of 13.1% from the February 28th total of 4,340,000 shares. Based on an average trading volume of 1,320,000 shares, the short-interest ratio is presently 3.7 days.
View Illumina's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our ILMN earnings forecast.

Illumina, Inc. (NASDAQ:ILMN) posted its earnings results on Tuesday, February, 7th. The life sciences company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.25 by $0.11. The life sciences company had revenue of $1.08 billion for the quarter, compared to analysts' expectations of $1.07 billion. Illumina had a positive trailing twelve-month return on equity of 3.79% and a negative net margin of 96.12%. The company's quarterly revenue was down 9.2% compared to the same quarter last year. During the same period in the previous year, the business earned $0.75 EPS.
Read the conference call transcript.

ETFs with the largest weight of Illumina (NASDAQ:ILMN) stock in their portfolio include First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), VanEck Biotech ETF (BBH), First Trust NYSE Arca Biotechnology Index Fund (FBT), Global X Genomics & Biotechnology ETF (GNOM), Global X Telemedicine & Digital Health ETF (EDOC), iShares Biotechnology ETF (IBB), Invesco Nasdaq Biotechnology ETF (IBBQ) and ProShares Ultra Nasdaq Biotechnology (BIB).

Illumina issued an update on its FY23 earnings guidance on Tuesday, February, 7th. The company provided earnings per share (EPS) guidance of $1.25-1.50 for the period, compared to the consensus estimate of $1.38. The company issued revenue guidance of +7-10% yr/yr to $4.9-5.04 billion, compared to the consensus revenue estimate of $4.97 billion.

496 employees have rated Illumina Chief Executive Officer Francis deSouza on Glassdoor.com. Francis deSouza has an approval rating of 92% among the company's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), Walt Disney (DIS), PayPal (PYPL), Salesforce (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

Illumina's stock is owned by a number of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (10.60%), Edgewood Management LLC (4.12%), Polen Capital Management LLC (3.21%), Alliancebernstein L.P. (2.46%), Geode Capital Management LLC (1.83%) and Price T Rowe Associates Inc. MD (1.34%). Insiders that own company stock include Aimee L Hoyt, Alexander Aravanis, Charles Dadswell, Frances Arnold, Francis A Desouza, Francis A Desouza, Jay T Flatley, Karen K Mcginnis, Mostafa Ronaghi, Oene Mark Van, Phillip G Febbo, Robert P Ragusa, Sam Samad, Susan H Tousi and Susan H Tousi.
View institutional ownership trends.

Shares of ILMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ILMN stock can currently be purchased for approximately $217.82.

Illumina (NASDAQ:ILMN) has a market capitalization of $34.42 billion and generates $4.58 billion in revenue each year. The life sciences company earns $-4,404,000,000.00 in net income (profit) each year or ($28.00) on an earnings per share basis.

The company employs 10,260 workers across the globe.

Illumina's mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The official website for the company is www.illumina.com. The life sciences company can be reached via phone at (858) 202-4500, via email at ir@illumina.com, or via fax at 858-202-4766.